107 related articles for article (PubMed ID: 27453282)
41. Cl-IB-MECA enhances TRAIL-induced apoptosis via the modulation of NF-kappaB signalling pathway in thyroid cancer cells.
Morello S; Sorrentino R; Porta A; Forte G; Popolo A; Petrella A; Pinto A
J Cell Physiol; 2009 Nov; 221(2):378-86. PubMed ID: 19562684
[TBL] [Abstract][Full Text] [Related]
42. Bio-active Natural Products with TRAIL-Resistance Overcoming Activity.
Ahmed F; Ishibashi M
Chem Pharm Bull (Tokyo); 2016; 64(2):119-27. PubMed ID: 26833440
[TBL] [Abstract][Full Text] [Related]
43. Parthenolide enhances sensitivity of colorectal cancer cells to TRAIL by inducing death receptor 5 and promotes TRAIL-induced apoptosis.
Kim SL; Liu YC; Park YR; Seo SY; Kim SH; Kim IH; Lee SO; Lee ST; Kim DG; Kim SW
Int J Oncol; 2015 Mar; 46(3):1121-30. PubMed ID: 25502339
[TBL] [Abstract][Full Text] [Related]
44. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase.
Nakshatri H; Rice SE; Bhat-Nakshatri P
Oncogene; 2004 Sep; 23(44):7330-44. PubMed ID: 15286701
[TBL] [Abstract][Full Text] [Related]
45. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells.
Xu W; Neckers L
Clin Cancer Res; 2007 Mar; 13(6):1625-9. PubMed ID: 17363512
[No Abstract] [Full Text] [Related]
46. NF-kappa B does not modulate sensitivity of renal carcinoma cells to TNF alpha-related apoptosis-inducing ligand (TRAIL).
Pawlowski JE; Nesterov A; Scheinman RI; Johnson TR; Kraft AS
Anticancer Res; 2000; 20(6B):4243-55. PubMed ID: 11205254
[TBL] [Abstract][Full Text] [Related]
47. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.
Rohwer N; Cramer T
Drug Resist Updat; 2011 Jun; 14(3):191-201. PubMed ID: 21466972
[TBL] [Abstract][Full Text] [Related]
48. TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells.
Heijink DM; Jalving M; Oosterhuis D; Sloots IA; Koster R; Hollema H; Kleibeuker JH; Koornstra JJ; de Vries EG; de Jong S
J Pathol; 2011 Feb; 223(3):378-89. PubMed ID: 21171083
[TBL] [Abstract][Full Text] [Related]
49. [Drug resistance mediated by survival- and growth-promoting signaling pathways].
Fujita N
Gan To Kagaku Ryoho; 2009 Apr; 36(4):567-71. PubMed ID: 19381028
[TBL] [Abstract][Full Text] [Related]
50. Key cell signaling pathways modulated by zerumbone: role in the prevention and treatment of cancer.
Prasannan R; Kalesh KA; Shanmugam MK; Nachiyappan A; Ramachandran L; Nguyen AH; Kumar AP; Lakshmanan M; Ahn KS; Sethi G
Biochem Pharmacol; 2012 Nov; 84(10):1268-76. PubMed ID: 22842489
[TBL] [Abstract][Full Text] [Related]
51. Deoxyelephantopin impairs growth of cervical carcinoma SiHa cells and induces apoptosis by targeting multiple molecular signaling pathways.
Farha AK; Dhanya SR; Mangalam SN; Geetha BS; Latha PG; Remani P
Cell Biol Toxicol; 2014 Dec; 30(6):331-43. PubMed ID: 25260383
[TBL] [Abstract][Full Text] [Related]
52. Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells.
Li YW; Zhu GY; Shen XL; Chu JH; Yu ZL; Fong WF
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1315-23. PubMed ID: 21461888
[TBL] [Abstract][Full Text] [Related]
53. Rational targeting of Notch signaling in cancer.
Rizzo P; Osipo C; Foreman K; Golde T; Osborne B; Miele L
Oncogene; 2008 Sep; 27(38):5124-31. PubMed ID: 18758481
[TBL] [Abstract][Full Text] [Related]
54. β-elemene reverses the drug resistance of lung cancer A549/DDP cells via the mitochondrial apoptosis pathway.
Yao CC; Tu YR; Jiang J; Ye SF; Du HX; Zhang Y
Oncol Rep; 2014 May; 31(5):2131-8. PubMed ID: 24627125
[TBL] [Abstract][Full Text] [Related]
55. Susceptibility of cholangiocarcinoma cells to parthenolide-induced apoptosis.
Kim JH; Liu L; Lee SO; Kim YT; You KR; Kim DG
Cancer Res; 2005 Jul; 65(14):6312-20. PubMed ID: 16024633
[TBL] [Abstract][Full Text] [Related]
56. Proteomics for identifying mechanisms and biomarkers of drug resistance in cancer.
Li XH; Li C; Xiao ZQ
J Proteomics; 2011 Nov; 74(12):2642-9. PubMed ID: 21964283
[TBL] [Abstract][Full Text] [Related]
57. alpha-TEA inhibits survival and enhances death pathways in cisplatin sensitive and resistant human ovarian cancer cells.
Yu W; Shun MC; Anderson K; Chen H; Sanders BG; Kline K
Apoptosis; 2006 Oct; 11(10):1813-23. PubMed ID: 16850165
[TBL] [Abstract][Full Text] [Related]
58. Sesquiterpene dimmer (DSF-27) inhibits the release of neuroinflammatory mediators from microglia by targeting spleen tyrosine kinase (Syk) and Janus kinase 2 (Jak2): Two major non-receptor tyrosine signaling proteins involved in inflammatory events.
Zeng KW; Wang S; Dong X; Jiang Y; Jin HW; Tu PF
Toxicol Appl Pharmacol; 2014 Mar; 275(3):244-56. PubMed ID: 24486434
[TBL] [Abstract][Full Text] [Related]
59. Citrus fruits and their bioactive ingredients: leading four horsemen from front.
Farooqi AA; Wang Z; Hasnain S; Attar R; Aslam A; Mansoor Q; Ismail M
Asian Pac J Cancer Prev; 2015; 16(6):2575-80. PubMed ID: 25824799
[TBL] [Abstract][Full Text] [Related]
60. The Ferrous Awakens.
Rennekamp AJ
Cell; 2017 Nov; 171(6):1225-1227. PubMed ID: 29195064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
